Application of human HHIP mRNA in the diagnosis and targeted therapy of esophageal squamous cell carcinoma
By detecting and upregulating the expression level of HHIP mRNA in esophageal squamous cell carcinoma, the problem of insufficient driver gene discovery in the diagnosis and treatment of esophageal squamous cell carcinoma in the prior art is solved, significantly improving diagnostic specificity and sensitivity, and inhibiting The proliferation and invasion ability of cancer cells has been improved.
Patent Information
- Application Number
- CN202410214468.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-27
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-02-27
AI Technical Summary
The prior art has insufficient effective driver gene discovery in the diagnosis and treatment of esophageal squamous cell carcinoma, which makes it difficult for clinical treatment to break through the problems of high invasiveness and low survival rates.
Human HHIP mRNA expression levels were detected by designing specific primers and upregulating HHIP mRNA using exogenous HHIP mRNA expression plasmids for diagnosis and targeted therapy of esophageal squamous cell carcinoma.
Effectively detect the differences in expression of HHIP mRNA in esophageal squamous cell carcinoma, significantly improve diagnostic specificity and sensitivity, and significantly inhibit the proliferation, migration and invasion of cancer cells by upregulating the expression level of HHIP mRNA, improving the therapeutic effect.
Smart Images

Figure CN118186079B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to application of human HHIP mRNA in diagnosis and targeted treatment of esophageal squamous cell carcinoma, a detection kit and an exogenous expression plasmid, and belongs to the technical field of biomedicine. Background Art
[0002] Esophageal cancer is a common malignant tumor of the human digestive tract. Its high invasiveness and tumor heterogeneity have always been bottlenecks that are difficult to break through in the clinical treatment of esophageal cancer. About 50% of the new cases in the world occur in China each year, posing a huge threat to the lives and health of the Chinese people. The pathological type of esophageal cancer patients in my country is mainly squamous cell carcinoma. At present, the clinical treatment method is mainly surgical resection, assisted by chemotherapy, immunotherapy, etc. The overall 5-year survival rate of patients is less than 20%. Therefore, discovering new driver genes for the occurrence and development of esophageal squamous cell carcinoma and clarifying their biological roles and molecular mechanisms in the malignant progression of esophageal squamous cell carcinoma are of great significance for promoting the development of clinical diagnosis and treatment strategies for esophageal squamous cell carcinoma and improving patient prognosis.
[0003] Polymerase Chain Reaction (PCR) is based on the principle of complementary base pairing, with DNA fragments as templates, and specifically amplifies the fragments between DNA sequences recognized by specific primer pairs. This technology has shown very high sensitivity and specificity in detecting the expression level of target gene mRNA. In addition, compared with other technologies, such as Sanger sequencing and second-generation sequencing, PCR technology has the advantages of simple operation and low cost in detecting the expression level of specific gene mRNA. The complete PCR process for detecting the expression level of target gene mRNA includes two major steps: reverse transcription and real-time fluorescence quantification. The specificity of the primer determines whether it can effectively bind to the target mRNA reverse transcription product (cDNA fragment) and the accuracy of the final quantitative expression level of the target gene mRNA. Therefore, the design of specific primers for PCR is extremely important. Summary of the invention
[0004] In view of the deficiencies of the prior art, the present invention provides the use of human HHIP mRNA in the diagnosis and targeted treatment of esophageal squamous cell carcinoma, as well as a detection kit and an exogenous expression plasmid.
[0005] The technical solution of the present invention is as follows:
[0006] Application of a reagent for detecting human HHIP mRNA expression level in the preparation of clinical diagnostic products for esophageal squamous cell carcinoma.
[0007] Preferably according to the present invention, the nucleotide sequence of the HHIP mRNA is as shown in SEQ NO.1.
[0008] Preferably, according to the present invention, the reagent for detecting the expression level of human HHIP mRNA includes a substance that specifically recognizes the cDNA of the reverse transcription product of human HHIP mRNA;
[0009] The substance that specifically recognizes the cDNA of the reverse transcription product of human HHIP mRNA is the upstream primer shown in SEQ ID NO.2 and the downstream primer shown in SEQ ID NO.3.
[0010] Preferably according to the present invention, the detection sample of the reagent for detecting the expression level of human HHIP mRNA is selected from cells, tissues, plasma or serum.
[0011] Application of a substance that specifically upregulates HHIP mRNA expression level in the preparation of a targeted therapeutic product for esophageal squamous cell carcinoma.
[0012] Preferably according to the present invention, the nucleotide sequence of the HHIP mRNA is as shown in SEQ NO.1.
[0013] Preferably according to the present invention, the substance that specifically upregulates the expression level of HHIP mRNA is an exogenous human HHIP mRNA expression plasmid.
[0014] Further preferably, the exogenous human HHIP mRNA expression plasmid contains the HHIP gene coding sequence; the HHIP gene coding sequence is shown in SEQ ID NO.4.
[0015] A kit for clinical diagnosis of esophageal squamous cell carcinoma, comprising a primer pair for specifically amplifying cDNA of a reverse transcription product of HHIPmRNA;
[0016] The primer pair for specifically amplifying the cDNA of the HHIP mRNA reverse transcription product is the upstream primer shown in SEQ ID NO.2 and the downstream primer shown in SEQ ID NO.3.
[0017] Preferably according to the present invention, the kit further comprises a detection reagent for real-time fluorescence quantitative PCR.
[0018] A drug for targeted treatment of esophageal squamous cell carcinoma, comprising an exogenous human HHIP mRNA expression plasmid that specifically upregulates the expression level of HHIP mRNA;
[0019] The exogenous human HHIP mRNA expression plasmid contains the HHIP gene coding sequence; the HHIP gene coding sequence is shown in SEQ ID NO.4.
[0020] Beneficial effects:
[0021] The present invention first discovered that the expression level of HHIP mRNA in esophageal squamous cell carcinoma tumor tissue was significantly downregulated compared with the adjacent normal esophageal mucosa, and designed a specific primer pair that can effectively detect the expression level of HHIP mRNA in esophageal squamous cell carcinoma tumor tissue and adjacent normal esophageal mucosa, as well as an exogenous human HHIP mRNA expression plasmid that specifically upregulates the expression level of HHIP mRNA. The present invention experiments have shown that the application of exogenous human HHIP mRNA expression plasmid can effectively upregulate the expression level of HHIP in esophageal squamous cell carcinoma cells, while significantly inhibiting their cell proliferation, migration and invasion ability. Therefore, the present invention uses HHIP mRNA as a target for the clinical diagnosis and treatment of esophageal squamous cell carcinoma, and proposes the use of HHIP mRNA in the clinical diagnosis and targeted treatment of esophageal squamous cell carcinoma, especially in the preparation of clinical diagnosis kits and targeted therapeutic drugs for esophageal squamous cell carcinoma. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The primer pairs provided by the present invention and the reverse transcription-real-time fluorescence quantitative PCR technology were used to detect the expression level of HHIP mRNA in 30 pairs of esophageal squamous cell carcinoma tumor tissues and adjacent normal esophageal mucosa. The expression level of HHIP mRNA in adjacent normal esophageal mucosa tissues was used as a reference to calculate the relative expression level of HHIP mRNA in esophageal squamous cell carcinoma tumor tissues, and the paired t The statistical significance of expression differences was analyzed.
[0023] Figure 2 The receiver operating characteristic curve (ROC) was used to evaluate the specificity and sensitivity of HHIP mRNA expression level in the clinical diagnosis of esophageal squamous cell carcinoma.
[0024] Figure 3 The exogenous human HHIP mRNA expression plasmid (HHIP) and the empty vector control plasmid (Vector) provided by the present invention were respectively transfected into the esophageal squamous cell carcinoma cell line (KYSE-150 cells), and the cell RNA was extracted, and reverse PCR was performed, and then fluorescence quantitative PCR was performed to detect the expression level of HHIP mRNA, and the unpaired t-test was used to clarify the statistical significance of the expression difference.
[0025] Figure 4 KYSE-150 cells were selected and transfected with HHIP and Vector expression plasmids, respectively. CCK-8 assay was used to evaluate the cell proliferation ability, and two-way ANOVA test was used to verify the statistical significance of the differences among the groups.
[0026] Figure 5KYSE-150 cells were selected and transfected with HHIP and Vector expression plasmids, respectively. Transwell assay was used to detect cell migration and invasion abilities, and unpaired t-test was used to clarify the statistical significance of expression differences. DETAILED DESCRIPTION
[0027] The technical solution of the present invention is further described below in conjunction with experimental examples, but the protection scope of the present invention is not limited thereto. The reagents and materials involved in the examples are all common commercially available products unless otherwise specified.
[0028] The collection and testing of surgical resection specimens from patients with esophageal squamous cell carcinoma involved in the examples were approved by the Medical Ethics Committee of the Second Hospital of Shandong University, and the informed consent of the patients was obtained.
[0029] Human esophageal squamous cell carcinoma cell line KYSE-150 cells were purchased from the Cell Bank of Type Culture Collection Committee of the Chinese Academy of Sciences.
[0030] Example 1
[0031] Thirty pairs of surgically removed esophageal squamous cell carcinoma specimens (including tumors and adjacent normal esophageal mucosal tissues) were collected, and total RNA was extracted from the samples. The primer pairs provided by the present invention and reverse transcription-real-time fluorescence quantitative PCR (RT-qPCR) technology were used to detect the expression level of HHIP mRNA. The primer pair sequences used to specifically recognize the cDNA of the reverse transcription product of HHIP mRNA are shown in SEQ ID NO.2 and SEQ ID NO.3. The detection results are shown in Figure 1 shown.
[0032] Depend on Figure 1 It can be seen that the expression level of HHIP mRNA in esophageal squamous cell carcinoma tumor tissue (ESCC) is significantly lower than that in the adjacent normal esophageal mucosal tissue (Normal), which indicates that HHIP mRNA may become a potential diagnostic marker for esophageal squamous cell carcinoma. The primer pair provided by the present invention can also be used in the clinical diagnosis of esophageal squamous cell carcinoma.
[0033] The postoperative pathological results of the 30 patients enrolled in the above group were all confirmed to be esophageal squamous cell carcinoma, and none of them had received chemoradiotherapy or immunotherapy before surgery.
[0034] The specific implementation process is as follows:
[0035] (1) Sample collection: 30 pairs of surgical specimens of esophageal squamous cell carcinoma were obtained from the Department of Thoracic Surgery, The Second Hospital of Shandong University. Tumor tissues were obtained from the central non-necrotic site, and adjacent normal esophageal mucosa was obtained from an area greater than 5 cm away from the tumor edge. They were quickly frozen in liquid nitrogen and stored at -80°C for future use.
[0036] (2) RNA extraction: RNA-Quick Purification Kit (Shanghai Yishan, RN001) was used to extract total RNA according to the instructions. The integrity of RNA was tested by agarose gel electrophoresis, and the concentration and purity of RNA were tested by NanoDrop2000.
[0037] (3) RT-qPCR: The lnRcute lncRNA cDNA First-Strand Synthesis Kit (TIANGEN, KR202) was used to remove the genomic DNA mixed in the mRNA extracted in step (2), and reverse transcription was performed using the mRNA as a template; a primer pair that specifically recognizes HHIP mRNA (SEQ ID NO.2 and SEQ ID NO.3) and PowerSYBR™ Green PCR premix (Thermo Fisher Scientific, 4367659) were used to perform qPCR reactions to detect the expression level of HHIP mRNA. The qPCR reactions were performed using a real-time fluorescence quantitative PCR instrument, QuantStudioTM 5 System (ThermoFisher Scientific); the expression level of ACTB mRNA was selected as the internal reference, and the expression level of HHIP mRNA was determined according to 2 -ΔΔCT The relative expression level of HHIP mRNA was calculated by the method, and the statistical significance of expression difference was analyzed by paired t test.
[0038] The nucleotide sequences of the primer pairs are as follows:
[0039] Upstream primer: 5′-TCCACGATCCAGGCAGATGT-3′ (SEQ ID NO. 2);
[0040] Downstream primer: 5'-TCCACCAACCAAAGGACCAT-3' (SEQ ID NO. 3).
[0041] System for removing genomic DNA: 5×gDNA Buffer 2μL, RNase-Free ddH2O 6μL, RNA (250ng / μL) 2μL; reaction conditions: incubate at 42℃ for 3 minutes, then place on ice for later use.
[0042] Reverse transcription PCR system: 2μL lnR-RT Primer Mix, 1μL lnR-RT Enzyme Mix, 2μL 10×lnR-RT Buffer, 5μL RNase-Free ddH2O, 10μL of the above genomic DNA removal system product; reaction conditions: incubate at 42°C for 15 minutes, incubate at 95°C for 3 minutes, and store at 4°C for later use.
[0043] Real-time fluorescence quantitative PCR system: 1 μL of the above reverse transcription system product, 1 μL of primer diluent (1 μM), 5 μL of PowerSYBR™ Green PCR premix, 3 μL of RNase-Free ddH2O. Reaction conditions: 95°C pre-denaturation for 3 minutes; 95°C denaturation for 15 seconds, 62°C annealing for 10 seconds, 72°C extension for 20 seconds, a total of 40 cycles; 95°C denaturation for 15 seconds, 60°C incubation for 60 seconds, and 95°C incubation for 1 second.
[0044] The reagents used in the above steps were from lnRcute lncRNA cDNA First-Strand Synthesis Kit (TIANGEN, KR202) and Power SYBR™ Green PCR Master Mix Kit (Thermo Fisher Scientific, 4367659).
[0045] Example 2
[0046] The 30 pairs of esophageal squamous cell carcinoma samples collected in Example 1 were tested for HHIP mRNA expression levels. The specific method was as described in Example 1. The receiver operating characteristic curve (ROC) was used to evaluate the specificity and sensitivity of HHIP mRNA expression levels in the diagnosis of esophageal squamous cell carcinoma. The test results were as follows: Figure 2 shown.
[0047] Depend on Figure 2 It can be seen that the area under the ROC curve (AUC) is 0.9222 (95% CI: 0.8598-0.9847). When the Youden index is the largest, its specificity is 86.67% and its sensitivity is 80.00%, which indicates that the expression level of HHIPmRNA has good efficacy in the clinical diagnosis of esophageal squamous cell carcinoma.
[0048] Example 3
[0049] An exogenous human HHIP mRNA expression plasmid (HHIP) and an empty vector control plasmid (Vector) were designed to specifically upregulate the expression level of HHIP mRNA. The HHIP gene coding sequence contained in the HHIP plasmid is shown in SEQ ID NO.4. The plasmid can overexpress HHIP mRNA. Esophageal squamous cell carcinoma cell line (KYSE-150 cells) was selected and transfected with exogenous human HHIP mRNA expression plasmid (HHIP) and empty vector control plasmid (Vector), respectively. RNA of the above transfected cells was extracted and reverse transcribed. Then, the primer pair of SEQ ID NO.2 and SEQ ID NO.3 was used for fluorescence quantitative PCR to detect the expression level of HHIP mRNA. The specific results are shown in FIG. Figure 3 As shown;
[0050] Depend on Figure 3 It can be seen that after KYSE-150 cells were transfected with exogenous human HHIP mRNA expression plasmid (HHIP), the expression level of HHIP mRNA in KYSE-150 cells increased significantly.
[0051] The specific implementation process is as follows:
[0052] (1) Designing an exogenous human HHIP mRNA expression plasmid (HHIP) and an empty vector plasmid (Vector), wherein the HHIP gene coding sequence contained in the HHIP plasmid is shown in SEQ ID NO.4;
[0053] (2) Digest, centrifuge and collect KYSE-150 cells, plate them in 6-well plates, and wait until the growth density reaches 60-70%. Use Lipofectamine 3000 Reagent (Invitrogen, L3000001) to transfect HHIP or Vector plasmid into the cells. After 48 hours, collect the cells, extract mRNA and perform RT-qPCR. The specific steps are as shown in Example 1.
[0054] Example 4
[0055] KYSE-150 cells were selected and transfected with exogenous human HHIP mRNA expression plasmid (HHIP) and empty vector control plasmid (Vector), respectively. CCK-8 assay was used to detect the effect of exogenous human HHIP mRNA expression plasmid (HHIP) on the proliferation of KYSE-150 cells. The specific results are as follows Figure 4 shown.
[0056] Depend on Figure 4It can be seen that the proliferation ability of KYSE-150 cells can be significantly inhibited after the expression level of HHIP mRNA in KYSE-150 cells is upregulated by using exogenous human HHIP mRNA expression plasmid.
[0057] (1) Select KYSE-150 cells and transfect them with HHIP or Vector plasmid, respectively. The specific steps are as shown in Example 3;
[0058] (2) Count cells and adjust the cell concentration to 20,000 cells / mL of culture medium. Add the cell suspension to a 96-well plate (100 mL / well). Plate 4 replicate wells in each group, for a total of 4 groups (for initial and 1, 2, and 3 day measurements). After placing in a cell culture incubator for 2 to 6 hours, add 10 μL of CCK-8 reagent (TargetMol, C0005) to each well, and then incubate in a 37°C incubator for 1 hour. After a brief shake, use an ELISA reader to measure the absorbance at 450 nm. This is the initial absorbance value of the plated cells. Repeat the above operation every 24 hours, and record the absorbance values after 1, 2, and 3 days of cell growth. A two-way ANOVA test was used to determine the statistical significance of the differences between the groups.
[0059] Example 5
[0060] KYSE-150 cells were selected, and exogenous human HHIP mRNA expression plasmid (HHIP) and empty vector control plasmid (Vector) were transfected into KYSE-150 cells respectively. The specific experimental method was the same as that in Example 3. Transwell assay was used to detect the effect of the expression of exogenous human HHIP mRNA expression plasmid (HHIP) on the migration and invasion ability of KYSE-150 cells. The specific results are as follows: Figure 5 As shown, Figure 5 The left side in the middle shows the results of cell migration, and the right side shows the results of cell invasion.
[0061] Depend on Figure 5 It can be seen that the application of exogenous human HHIP mRNA expression plasmid to upregulate the expression level of HHIP mRNA in KYSE-150 cells can significantly weaken the migration and invasion abilities of KYSE-150 cells.
[0062] The specific implementation process is as follows:
[0063] (1) Select KYSE-150 cells and transfect them with HHIP or Vector plasmid, respectively. The specific steps are as shown in Example 3;
[0064] (2) Resuspend the remaining cell pellet in serum-free medium and adjust the concentration to 100,000 cells / mL medium. Add complete medium (600 μL / well) to the 24-well plate. Place the Transwell chamber (Corning, 3422) pre-coated with or without matrix gel in the 24-well plate. Add 200 μL of cell suspension to each chamber. Carefully transfer the 24-well plate to the cell culture incubator and culture at 37°C and 5% CO2 for 48 hours. Discard the medium and wash the chamber with PBS buffer. Fix with 4% paraformaldehyde at room temperature for 15 minutes. Add 0.1% crystal violet to the chamber and place it at room temperature overnight. After washing with PBS buffer, use a cotton swab to remove cells attached to the side of the chamber. Take pictures and count the perforated cells under a microscope. Apply Student's t Tests were performed to determine the statistical significance of differences between groups.
[0065] The above-described embodiments are only preferred specific implementation schemes of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. Use of a reagent for detecting human HHIP mRNA expression level in the preparation of a clinical diagnostic product for esophageal squamous cell carcinoma, characterized in that: The nucleotide sequence of the HHIP mRNA is shown in SEQ NO.
1.
2. The use according to claim 1, characterized in that The reagent for detecting the expression level of human HHIP mRNA includes a substance that specifically recognizes the cDNA of the reverse transcription product of human HHIP mRNA; The substance that specifically recognizes the cDNA of the reverse transcription product of human HHIP mRNA is the upstream primer shown in SEQ ID NO.2 and the downstream primer shown in SEQ ID NO.
3.
3. The use according to claim 1, characterized in that The detection sample of the reagent for detecting the expression level of human HHIP mRNA is selected from cells, tissues, plasma or serum.
4. Use of a substance that specifically upregulates the expression level of HHIP mRNA in the preparation of a targeted therapeutic product for esophageal squamous cell carcinoma, characterized in that: The nucleotide sequence of the HHIP mRNA is shown in SEQ NO.
1.
5. The use according to claim 4, characterized in that The substance that specifically upregulates the expression level of HHIP mRNA is an exogenous human HHIP mRNA expression plasmid; The exogenous human HHIP mRNA expression plasmid contains the HHIP gene coding sequence; the HHIP gene coding sequence is shown in SEQ ID NO.4.
